Sun Pharma Advanced Research Company (SPARC) has announced completion of Phase 3 studies for a new dry powder inhaler and its intention to launch a product based on the novel DPI in India by the end of the 2nd quarter of the fiscal year. In addition, the company said, it plans to file an IND in the US by the end of the fiscal year.
The DPI delivers a dry powder ICS/beta agonist formulation with the same efficacy as the Advair Diskus at only half the dose, the company claims, and the device also has “a visual, audible and tactile feedback upon dose administration. A glow-in-the-dark feature ensured easy night-time use.”
The company also updated its progress on SUN-597, a glucocorticoid, saying that the inhaled version is undergoing preclinical toxicity studies, and the nasal version is in Phase 1b. Plans are to file an IND for inhaled SUN-597 by the end of the fiscal year.
Read the SPARC press release.
